Skip to main content

Corporate Profile

PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

Recent Updates

PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh 

| News, Press Releases | No Comments
PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh PrintBio was founded by Rapha Capital Management, LLC and its investors through its SPV, Rapha Capital Investment XIV,…

Doctors Transplant Ear of Human Cells, Made by 3-D Printer

| News | No Comments
3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a body part with a patent’s own cells. View Full New…

Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

| Press Releases | No Comments
AuriNovo™ an investigational, 3D-bioprinted implant was created using a proprietary process leveraging the patient’s own tissue to generate an implantable ear Phase 1/2a clinical trial enrolling patients with microtia, a…